Holen Sie sich die Stockscreener-App
44.06
1.78%
0.77
Handel nachbörslich:
43.80
-0.26
-0.59%
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines CEO Mark Goldsmith sells $531,860 in stock By Investing.com - Investing.com Australia
Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in - EIN News
Revolution Medicines general counsel sells $72,600 in stock By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark Goldsmith sells $531,860 in stock - Investing.com India
Revolution Medicines COO Margaret Horn sells shares worth $196,553 By Investing.com - Investing.com Canada
Revolution Medicines CFO Jack Anders sells shares worth $119,639 By Investing.com - Investing.com South Africa
Revolution Medicines, Inc. (NASDAQ:RVMD) COO Sells $196,536.60 in Stock - MarketBeat
Revolution Medicines general counsel sells $72,600 in stock - Investing.com
Revolution Medicines CFO Jack Anders sells shares worth $119,639 - Investing.com
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 11,714 Shares of Stock - MarketBeat
Jack Anders Sells 2,635 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock - MarketBeat
Revolution Medicines COO Margaret Horn sells shares worth $196,553 - Investing.com
Finance Watch: FOPO Surge Continues With Big Offerings From Revolution, NewAmsterdam - Citeline News & Insights
(RVMD) Technical Data - Stock Traders Daily
Revolution Medicines' SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com
Wilmington Savings Fund Society FSB Invests $801,000 in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Barclays PLC Buys 192,021 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
One Revolution Medicines Insider Raised Their Stake In The Previous Year - Yahoo Finance
State Street Corp Has $239.43 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Verition Fund Management LLC Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines director Schroeder acquires $59.9m in stock By Investing.com - Investing.com Nigeria
Revolution Medicines director Schroeder acquires $59.9m in stock - Investing.com India
Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Price Target at $63.67 - MarketBeat
What is HC Wainwright's Estimate for RVMD FY2024 Earnings? - MarketBeat
How to Take Advantage of moves in (RVMD) - Stock Traders Daily
Revolution Medicines completes $823 million public offering By Investing.com - Investing.com Canada
Revolution Medicines completes $823 million public offering - Investing.com
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewswire
Latham Watkins Advises Revolution Medicines in Upsized US750 Million Public Offering of Common Stock - Latham & Watkins LLP
Revolution Medicines: Risky Buy On Recent Share Price Dip (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines price target raised to $87 from $82 at Guggenheim - Yahoo Finance
Top 3 Health Care Stocks That Could Blast Off In December - Benzinga
Janus Henderson Group PLC Acquires 1,497,026 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Edgestream Partners L.P. Invests $1.75 Million in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
27,400 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Erste Asset Management GmbH - MarketBeat
Revolution Medicines Prices $45 Million Stock, Warrant Offering - Marketscreener.com
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Revolution Medicines Announces Pricing of Upsized $750.0 - GlobeNewswire
Revolution Medicines' SWOT analysis: stock outlook amid RAS inhibitor progress - Investing.com
Revolution’s RAS Plans Move Ahead Despite Investors’ Safety Doubts - News & Insights
HighVista Strategies LLC Boosts Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Cinctive Capital Management LP Purchases 30,430 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines reports progress in cancer drug trials By Investing.com - Investing.com Canada
Revolution Medicines announces $600 million stock offering By Investing.com - Investing.com Canada
Revolution Medicines announces $600 million stock offering - Investing.com India
Revolution Medicines reports progress in cancer drug trials - Investing.com India
Revolution Medicines Launches $600 Million Offering of Common Shares - Marketscreener.com
Revolution Medicines Announces Commencement of Public Offering of Common Stock - The Manila Times
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option - StockTitan
Revolution Medicines reports promising trial results for cancer treatments - Investing.com India
Revolution Medicines Shares Drop on Clinical Data Update By Investing.com - Investing.com Nigeria
Revolution Medicines Shares Drop on Clinical Data Update - Investing.com India
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):